TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
Egetis Therapeutics AB (publ)
Closing information (x1000 NOK)
Closing information | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
Turnover |
58,351
|
21,378
|
37,295 |
Financial expenses |
6,990
|
662
|
183 |
Earnings before taxes |
-331,059
|
-183,318
|
-101,952 |
EBITDA |
-325,386
|
-184,831
|
-100,668 |
Total assets |
770,107
|
530,752
|
555,164 |
Current assets |
350,408
|
139,428
|
149,113 |
Current liabilities |
105,254
|
46,728
|
38,199 |
Equity capital |
552,710
|
478,821
|
513,980 |
- share capital |
15,601
|
10,689
|
8,473 |
Employees (average) |
27
|
15
|
11 |
Financial ratios
Fiscal year | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
Solvency |
71.8%
|
90.2%
|
92.6% |
Turnover per employee |
2,161
|
1,425
|
3,390 |
Profit as a percentage of turnover |
-567.4%
|
-857.5%
|
-273.4% |
Return on assets (ROA) |
-42.1%
|
-34.4%
|
-18.3% |
Current ratio |
332.9%
|
298.4%
|
390.4% |
Return on equity (ROE) |
-59.9%
|
-38.3%
|
-19.8% |
Change turnover |
35,456
|
-14,797
|
-2,359 |
Change turnover % |
155%
|
-41%
|
-6% |
Chg. No. of employees |
12
|
4
|
2 |
Chg. No. of employees % |
80%
|
36%
|
22% |
Total value of public sale
Fiscal year | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
Total value of public sale |
0
![]() |
0
![]() |
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.